For most of its life, AnaptysBio was a bet on science. It discovered drug candidates, ran trials, and hoped one would survive long enough to reach patients. Then, in December 2024, its most advanced self-funded program, a compound called ANB032 for eczema, failed its Phase 2b trial. The company that emerged from that failure looks almost nothing like the one that entered it.
On April 20, 2026, AnaptysBio completed a spin-off of its remaining drug-development operations into a new company called First Tracks Biotherapeutics. What stayed behind was a much simpler thing: a royalty collector. AnaptysBio now earns money when two drugs it once helped create, Jemperli and Quimilza, are sold by other companies. The stock has roughly doubled over the past year, then given back about a third of its peak. Those two facts sitting side by side are the story.
The story, briefly
The filed numbers show a company that has stopped spending on science and started collecting checks. Royalties from Jemperli are growing, the drug just won a new FDA approval, and a second drug faces an FDA decision in weeks. The stock is priced well below its own historical average on a revenue basis, but a lawsuit over the rights to its biggest asset could rewrite the math entirely. The open question is whether the royalty stream is as secure as the growth rate suggests.
What the filing shows
The 10-Q for the quarter ended September 30, 2026, filed November 12, tells a clean story on the revenue line and a complicated one in the footnotes. Collaboration revenue came in at $30.3 million for the quarter, and the company posted a small profit, the first positive quarterly earnings figure in years. For a company that was deeply in the red as recently as fiscal year 2024, that is a meaningful turn.
Almost all of that revenue came from Jemperli royalties, which reached $29.6 million in the quarter, up roughly a fifth from a year earlier. Think of it like a landlord whose tenant’s business is growing: the rent check gets bigger automatically as sales cross higher tiers. Quimilza royalties, by contrast, fell to less than a rounding error next to Jemperli, a fraction of what they were in the prior-year period.
The cash position as of September 30 stood at $153 million, and the company burned through a modest amount in operating cash during the quarter. At that rate, the existing cash covers operations for well over four years, and management stated in the filing that resources are sufficient for at least the next 12 months. For a royalty company with no lab costs, that is a comfortable position.
Two decisions, one lawsuit
The next few months carry more binary weight than the quarterly numbers suggest. In October 2026, the FDA granted accelerated approval to Jemperli for adults with stage II and III dMMR rectal cancer, the first immunotherapy cleared for that specific indication, according to company disclosures. That new label opens a patient population that did not exist for the drug before, and Jemperli has already crossed a billion dollars in cumulative revenue for calendar year 2026, growing roughly a third year over year, as CEO Dan Faga described at the UBS Global Biopharma Conference on November 17. Because royalty rates step up once annual sales cross certain thresholds, that milestone means AnaptysBio collects a larger slice of each additional dollar GSK earns.
Quimilza faces its own moment. The FDA accepted Vanda’s application for the drug in generalized pustular psoriasis, a rare and painful skin condition, with a decision date of December 12, 2026. An approval would not move the revenue needle much immediately, given how small Quimilza royalties already are, but it would establish a second approved indication and give the asset a longer commercial life.
Then there is the lawsuit. AnaptysBio is in litigation with GSK over the rights to dostarlimab, the molecule sold as Jemperli. Post-trial arguments were held October 20, 2026, and a judgment is expected sometime in late 2026 or early 2027. The dossier does not specify what AnaptysBio is seeking or what GSK is defending, and the filed documents do not quantify the financial exposure. The litigation outcome is the dominant uncertainty in the public record, and the filed documents do not quantify the financial exposure in either direction.
The math versus the mood
“The math” is what the filed fundamentals justify; “the mood” is what the market is currently paying. Our data show AnaptysBio trading at a price-to-sales ratio of 5.8 times, against its own decade median of 8.3 times, placing it in roughly the bottom 13th percentile of its own history on that measure. In plain terms, the market is paying less per dollar of revenue today than it has for most of the past ten years. Whether that reflects the lawsuit discount, the narrower business model, or simple post-rally fatigue is a question the numbers cannot answer on their own.
As of late October 2026, published analyst estimates on MarketBeat ranged from approximately $60 to $95 per share, reflecting divergent assumptions about the litigation outcome and the Quimilza decision. BullScope publishes no price targets of its own, and given the binary legal and regulatory events ahead, our methodology does not support a conditional range here. The spread itself illustrates how sensitive any valuation is to those two pending outcomes.
Reading the numbers
- $29.6 million in Q3 2026 Jemperli royalties (from the 10-Q filed November 12, 2026). This is the rent check AnaptysBio receives because GSK sells Jemperli. It grew from $24.9 million a year earlier, a roughly 19% rise. A household analogy: imagine owning a percentage of a neighbor’s business income, and that income grew by about a fifth in a year with no extra work required.
- $153 million cash position as of September 30, 2026 (same filing). At roughly $9.5 million of quarterly cash use, this covers about four years of operations at the current burn rate. For a company with no drug pipeline to fund, that is a deep cushion.
- $235 million in FY2025 revenue (from the 10-K for fiscal year ended December 31, 2025), up 157% from the prior year. Most of that jump came from a $50 million GSK milestone payment that was recognized in that period and did not repeat in Q3 2026. Strip the milestone out and the underlying royalty growth is real but more modest.
- Price-to-sales ratio of 5.8 times (our data). This is the price tag the market puts on each dollar of AnaptysBio’s annual revenue. At 5.8 times, it sits below the company’s own decade median of 8.3 times, meaning the stock is cheaper relative to its sales than it has been for most of its history. That gap could reflect the lawsuit risk, or it could reflect the simpler business model, or both.
Sources
- 10-Q for quarter ended September 30, 2026, SEC EDGAR
- 10-K for fiscal year ended December 31, 2025, SEC EDGAR
- 10-K for fiscal year ended December 31, 2024, SEC EDGAR
- AnaptysBio at UBS Global Biopharma Conference, November 17, 2026, Seeking Alpha
- AnaptysBio Q2 and transitional fiscal year press release, IR site
- ANB032 Phase 2b trial discontinuation announcement, IR site
- AnaptysBio analyst forecasts, MarketBeat
- AnaptysBio Q3 2026 revenue and EPS summary, TradingView









